Abstract
As the commercial market for therapeutic protein production from mammalian cells has expanded, so has the requirement for improved efficiency and stability of production. Rapid developments have been made in understanding the molecular environment of transgenes in chromatin, including elucidation of the contribution of epigenetic modifications to expression, and this understanding is being used to enhance expression from host cells. Technical advances surrounding the 'omics' revolution are enabling the rational identification of complex control factors that define the flow of information from transgene to desired protein. Using information from 'omics' interrogations, directed cell engineering has been employed to enhance the translational and secretory capacity of host cells. Taken together, these recent advances are likely to lead to improved routes for protein production in the future. © 2006 Elsevier Ltd. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 381-386 |
Number of pages | 5 |
Journal | Current Opinion in Biotechnology |
Volume | 17 |
Issue number | 4 |
DOIs | |
Publication status | Published - Aug 2006 |